Cargando…

Chemotherapy only in early-stage Hodgkin lymphoma: More relapses but “same” (or possibly worse) survival – Reconsidering the misguided trend to omit radiotherapy

The standard treatment of early-stage Hodgkin lymphoma (ESHL) as recommended by most national guidelines is combined modality treatment (CMT) that includes a short course ABVD followed by a small field of low dose radiotherapy (RT). Recently a trend to treat patients with more chemotherapy alone has...

Descripción completa

Detalles Bibliográficos
Autor principal: Yahalom, Joachim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4180027/
https://www.ncbi.nlm.nih.gov/pubmed/24939521
http://dx.doi.org/10.1007/s11899-014-0222-5
_version_ 1782337170123522048
author Yahalom, Joachim
author_facet Yahalom, Joachim
author_sort Yahalom, Joachim
collection PubMed
description The standard treatment of early-stage Hodgkin lymphoma (ESHL) as recommended by most national guidelines is combined modality treatment (CMT) that includes a short course ABVD followed by a small field of low dose radiotherapy (RT). Recently a trend to treat patients with more chemotherapy alone has been promoted by some claiming that chemotherapy alone is good enough, and the overall survival is similar. These arguments need to be carefully examined, and the risk of more chemotherapy upfront and salvage considered. The suggestion that interim PET will identify patients that can have similar results with chemotherapy alone has recently been questioned by the results of both European and UK studies. It is the subject of this critical review.
format Online
Article
Text
id pubmed-4180027
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-41800272014-10-08 Chemotherapy only in early-stage Hodgkin lymphoma: More relapses but “same” (or possibly worse) survival – Reconsidering the misguided trend to omit radiotherapy Yahalom, Joachim Curr Hematol Malig Rep Lymphomas (J Armitage, Section Editor) The standard treatment of early-stage Hodgkin lymphoma (ESHL) as recommended by most national guidelines is combined modality treatment (CMT) that includes a short course ABVD followed by a small field of low dose radiotherapy (RT). Recently a trend to treat patients with more chemotherapy alone has been promoted by some claiming that chemotherapy alone is good enough, and the overall survival is similar. These arguments need to be carefully examined, and the risk of more chemotherapy upfront and salvage considered. The suggestion that interim PET will identify patients that can have similar results with chemotherapy alone has recently been questioned by the results of both European and UK studies. It is the subject of this critical review. Springer US 2014-06-18 2014 /pmc/articles/PMC4180027/ /pubmed/24939521 http://dx.doi.org/10.1007/s11899-014-0222-5 Text en © The Author(s) 2014 https://creativecommons.org/licenses/by/4.0/ Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Lymphomas (J Armitage, Section Editor)
Yahalom, Joachim
Chemotherapy only in early-stage Hodgkin lymphoma: More relapses but “same” (or possibly worse) survival – Reconsidering the misguided trend to omit radiotherapy
title Chemotherapy only in early-stage Hodgkin lymphoma: More relapses but “same” (or possibly worse) survival – Reconsidering the misguided trend to omit radiotherapy
title_full Chemotherapy only in early-stage Hodgkin lymphoma: More relapses but “same” (or possibly worse) survival – Reconsidering the misguided trend to omit radiotherapy
title_fullStr Chemotherapy only in early-stage Hodgkin lymphoma: More relapses but “same” (or possibly worse) survival – Reconsidering the misguided trend to omit radiotherapy
title_full_unstemmed Chemotherapy only in early-stage Hodgkin lymphoma: More relapses but “same” (or possibly worse) survival – Reconsidering the misguided trend to omit radiotherapy
title_short Chemotherapy only in early-stage Hodgkin lymphoma: More relapses but “same” (or possibly worse) survival – Reconsidering the misguided trend to omit radiotherapy
title_sort chemotherapy only in early-stage hodgkin lymphoma: more relapses but “same” (or possibly worse) survival – reconsidering the misguided trend to omit radiotherapy
topic Lymphomas (J Armitage, Section Editor)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4180027/
https://www.ncbi.nlm.nih.gov/pubmed/24939521
http://dx.doi.org/10.1007/s11899-014-0222-5
work_keys_str_mv AT yahalomjoachim chemotherapyonlyinearlystagehodgkinlymphomamorerelapsesbutsameorpossiblyworsesurvivalreconsideringthemisguidedtrendtoomitradiotherapy